| Adverse events . | Total follow-up years: 196.1 . |
|---|---|
| Possibly related | 31 [15.8 per 100 patient-years] |
| Cutaneous rash | 10 |
| Headache | 6 |
| Arthralgia | 3 |
| Gastrointestinal | 2 |
| Vascular event | 2 |
| Hair loss | 2 |
| Fatigue | 1 |
| Panic attacks | 1 |
| Dry mouth | 1 |
| Severe hypocalcaemia and hypomagnesaemia | 1 |
| Nervous system event | 1 |
| Eye condition | 1 |
| Probably related | 9 [4.6 per 100 patient-years] |
| Cutaneous rash | 3 |
| Arthralgia | 2 |
| Headache | 1 |
| Injection reactions | 1 |
| Eye condition | 1 |
| Hair loss | 1 |
| Serious adverse events | 8 [4.1 per 100 patient-years] |
| Arthralgia | 4 |
| Infusion reaction | 1 |
| Vasculitis | 1 |
| Recurrent infections | 1 |
| Severe headache | 1 |
| Mild infections | 39 [19.9 per 100 patient-years] |
| Upper respiratory tract | 16 |
| Flu-like symptoms | 10 |
| Gastrointestinal | 6 |
| Soft tissue | 3 |
| Cold sore | 3 |
| Urinary tract | 1 |
| Moderate infections | 25 [12.7 per 100 patient-years] |
| Urinary tract | 7 |
| Upper respiratory tract | 7 |
| Skin | 3 |
| Soft tissue | 3 |
| Lower respiratory tract | 3 |
| Gynaecological | 1 |
| Flu-like | 1 |
| Severe infections | 6 [3.1 per 100 patient-years] |
| Gastrointestinal | 4 |
| Central catheter | 1 |
| Herpes zoster | 1 |
| Adverse events . | Total follow-up years: 196.1 . |
|---|---|
| Possibly related | 31 [15.8 per 100 patient-years] |
| Cutaneous rash | 10 |
| Headache | 6 |
| Arthralgia | 3 |
| Gastrointestinal | 2 |
| Vascular event | 2 |
| Hair loss | 2 |
| Fatigue | 1 |
| Panic attacks | 1 |
| Dry mouth | 1 |
| Severe hypocalcaemia and hypomagnesaemia | 1 |
| Nervous system event | 1 |
| Eye condition | 1 |
| Probably related | 9 [4.6 per 100 patient-years] |
| Cutaneous rash | 3 |
| Arthralgia | 2 |
| Headache | 1 |
| Injection reactions | 1 |
| Eye condition | 1 |
| Hair loss | 1 |
| Serious adverse events | 8 [4.1 per 100 patient-years] |
| Arthralgia | 4 |
| Infusion reaction | 1 |
| Vasculitis | 1 |
| Recurrent infections | 1 |
| Severe headache | 1 |
| Mild infections | 39 [19.9 per 100 patient-years] |
| Upper respiratory tract | 16 |
| Flu-like symptoms | 10 |
| Gastrointestinal | 6 |
| Soft tissue | 3 |
| Cold sore | 3 |
| Urinary tract | 1 |
| Moderate infections | 25 [12.7 per 100 patient-years] |
| Urinary tract | 7 |
| Upper respiratory tract | 7 |
| Skin | 3 |
| Soft tissue | 3 |
| Lower respiratory tract | 3 |
| Gynaecological | 1 |
| Flu-like | 1 |
| Severe infections | 6 [3.1 per 100 patient-years] |
| Gastrointestinal | 4 |
| Central catheter | 1 |
| Herpes zoster | 1 |
| Adverse events . | Total follow-up years: 196.1 . |
|---|---|
| Possibly related | 31 [15.8 per 100 patient-years] |
| Cutaneous rash | 10 |
| Headache | 6 |
| Arthralgia | 3 |
| Gastrointestinal | 2 |
| Vascular event | 2 |
| Hair loss | 2 |
| Fatigue | 1 |
| Panic attacks | 1 |
| Dry mouth | 1 |
| Severe hypocalcaemia and hypomagnesaemia | 1 |
| Nervous system event | 1 |
| Eye condition | 1 |
| Probably related | 9 [4.6 per 100 patient-years] |
| Cutaneous rash | 3 |
| Arthralgia | 2 |
| Headache | 1 |
| Injection reactions | 1 |
| Eye condition | 1 |
| Hair loss | 1 |
| Serious adverse events | 8 [4.1 per 100 patient-years] |
| Arthralgia | 4 |
| Infusion reaction | 1 |
| Vasculitis | 1 |
| Recurrent infections | 1 |
| Severe headache | 1 |
| Mild infections | 39 [19.9 per 100 patient-years] |
| Upper respiratory tract | 16 |
| Flu-like symptoms | 10 |
| Gastrointestinal | 6 |
| Soft tissue | 3 |
| Cold sore | 3 |
| Urinary tract | 1 |
| Moderate infections | 25 [12.7 per 100 patient-years] |
| Urinary tract | 7 |
| Upper respiratory tract | 7 |
| Skin | 3 |
| Soft tissue | 3 |
| Lower respiratory tract | 3 |
| Gynaecological | 1 |
| Flu-like | 1 |
| Severe infections | 6 [3.1 per 100 patient-years] |
| Gastrointestinal | 4 |
| Central catheter | 1 |
| Herpes zoster | 1 |
| Adverse events . | Total follow-up years: 196.1 . |
|---|---|
| Possibly related | 31 [15.8 per 100 patient-years] |
| Cutaneous rash | 10 |
| Headache | 6 |
| Arthralgia | 3 |
| Gastrointestinal | 2 |
| Vascular event | 2 |
| Hair loss | 2 |
| Fatigue | 1 |
| Panic attacks | 1 |
| Dry mouth | 1 |
| Severe hypocalcaemia and hypomagnesaemia | 1 |
| Nervous system event | 1 |
| Eye condition | 1 |
| Probably related | 9 [4.6 per 100 patient-years] |
| Cutaneous rash | 3 |
| Arthralgia | 2 |
| Headache | 1 |
| Injection reactions | 1 |
| Eye condition | 1 |
| Hair loss | 1 |
| Serious adverse events | 8 [4.1 per 100 patient-years] |
| Arthralgia | 4 |
| Infusion reaction | 1 |
| Vasculitis | 1 |
| Recurrent infections | 1 |
| Severe headache | 1 |
| Mild infections | 39 [19.9 per 100 patient-years] |
| Upper respiratory tract | 16 |
| Flu-like symptoms | 10 |
| Gastrointestinal | 6 |
| Soft tissue | 3 |
| Cold sore | 3 |
| Urinary tract | 1 |
| Moderate infections | 25 [12.7 per 100 patient-years] |
| Urinary tract | 7 |
| Upper respiratory tract | 7 |
| Skin | 3 |
| Soft tissue | 3 |
| Lower respiratory tract | 3 |
| Gynaecological | 1 |
| Flu-like | 1 |
| Severe infections | 6 [3.1 per 100 patient-years] |
| Gastrointestinal | 4 |
| Central catheter | 1 |
| Herpes zoster | 1 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
